OmniAb Announces Global Collaboration and License Agreement with Eli Lilly For New Ion Channel Program; OmniAb To Receive An Upfront Payment and Is Eligible To Receive Up to $370M In R&D and Commercial Milestone Payments

Benzinga Newsdesk www.benzinga.com Neutral 94.1%

Neg 0% Neu 94.1% Pos 0%

The therapeutic target and modality are undisclosed.

Comments

No comments yet. Be the first!